Clinical Trial Update: A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of Felmetatug Vedotin (SGN-B7H4V) in advanced solid tumors was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cholangiocarcinoma
• Endometrial Cancer
• Fallopian Tube Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Peritoneal Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Felmetatug Vedotin (SGN-B7H4V)

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: Ovarian Neoplasms, Peritoneal Neoplasms | Phase 1 | Status: TERMINATED